Enanta Pharmaceuticals (NASDAQ:ENTA) vs. ReNeuron Group (OTCMKTS:RNUGF) Critical Contrast

ReNeuron Group (OTCMKTS:RNUGF) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Earnings and Valuation

This table compares ReNeuron Group and Enanta Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ReNeuron Group	$640,000.00	N/A	-$6.52 million	N/A	N/A
Enanta Pharmaceuticals	$65.32 million	6.30	-$81.89 million	($3.83)	-3.72

ReNeuron Group has higher earnings, but lower revenue than Enanta Pharmaceuticals.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for ReNeuron Group and Enanta Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ReNeuron Group	0	0	0	0	0.00
Enanta Pharmaceuticals	1	0	6	0	2.71

Enanta Pharmaceuticals has a consensus price target of $20.33, suggesting a potential upside of 42.64%. Given Enanta Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Enanta Pharmaceuticals is more favorable than ReNeuron Group.

Profitability

This table compares ReNeuron Group and Enanta Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ReNeuron Group	N/A	N/A	N/A
Enanta Pharmaceuticals	-125.36%	-93.76%	-26.13%

Insider and Institutional Ownership

95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. 13.9% of Enanta Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

ReNeuron Group has a beta of -0.62, meaning that its share price is 162% less volatile than the S&P 500. Comparatively, Enanta Pharmaceuticals has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500.

Summary

Enanta Pharmaceuticals beats ReNeuron Group on 7 of the 11 factors compared between the two stocks.

About ReNeuron Group

ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized vesicles secreted by stem cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.